Wnt2 as a new therapeutic target in malignant pleural mesothelioma

Malignant mesothelioma of the pleura (MPM) is a highly aggressive neoplasm with a poor prognosis and limited treatment options. A better understanding of its pathogenesis is essential to developing alternative therapeutic strategies. We previously demonstrated that the Wnt signaling pathway is activated in MPM through the overexpression of disheveled proteins. To extend our knowledge of Wnt signaling activation in MPM, we performed Wnt‐specific microarrays in normal pleura and MPM. We found that the most common event in MPM was the upregulation of Wnt2. We inhibited Wnt2 by siRNA and a monoclonal anti‐Wnt2 antibody and analyzed their effects on apoptosis and downstream signaling effectors. We then assessed the antiproliferative effects of the Wnt2 antibody and Alimta, one of the current standard treatments of MPM. We confirmed Wnt2 overexpression at the mRNA and protein level in MPM cell lines and tissues. We then demonstrated that inhibition of Wnt2 by siRNA or a monoclonal antibody induces programmed cell death in MPM cells. We next analyzed the effects of the anti‐Wnt2 antibody and of Alimta on MPM cell proliferation. We found that although Wnt2 antibody by itself had less antiproliferative potency than Alimta, the two in combination had substantially more activity than Alimta alone. We thus propose that inhibition of Wnt2 is of therapeutic interest in the development of more effective treatments for MPM. © 2005 Wiley‐Liss, Inc.

[1]  Biao He,et al.  Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma , 2004, Oncogene.

[2]  K. Uematsu,et al.  Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells , 2004, Oncogene.

[3]  P. Ruffié,et al.  Malignant mesothelioma: Medical oncology: standards, new trends, trials—the French experience , 2004 .

[4]  A. Hanauske The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials. , 2004, Lung cancer.

[5]  Hedy L Kindler,et al.  Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. , 2004, Lung cancer.

[6]  N. Thatcher Second Heidelberg Thoracic Oncology Symposium on the Diagnosis and Treatment of Pleural Mesothelioma--introduction. , 2004, Lung cancer.

[7]  Amie Y Lee,et al.  Inhibition of Wnt-1 Signaling Induces Apoptosis in β-Catenin-Deficient Mesothelioma Cells , 2004, Cancer Research.

[8]  T. Kipps,et al.  Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Sabbioni,et al.  Simian virus 40 infection in humans and association with human diseases: results and hypotheses. , 2004, Virology.

[10]  A. Gazdar,et al.  Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. , 2003, Clinical lung cancer.

[11]  J. Collins,et al.  Cadherins, catenins and APC in pleural malignant mesothelioma , 2003, The Journal of pathology.

[12]  R. Holcombe,et al.  Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features , 2003, Molecular pathology : MP.

[13]  K. Uematsu,et al.  Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. , 2003, Cancer research.

[14]  U. Gatzemeier,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Behrens,et al.  The Wnt signaling pathway and its role in tumor development , 2003, Journal of Cancer Research and Clinical Oncology.

[16]  Gut reaction , 2002 .

[17]  M. Bittner,et al.  Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. , 2002, Cancer cell.

[18]  T. Tuschl,et al.  Analysis of gene function in somatic mammalian cells using small interfering RNAs. , 2002, Methods.

[19]  H. Kirikoshi,et al.  WNT2B2 mRNA, up-regulated in primary gastric cancer, is a positive regulator of the WNT- beta-catenin-TCF signaling pathway. , 2001, Biochemical and biophysical research communications.

[20]  M. Katoh,et al.  Differential regulation of WNT2 and WNT2B expression in human cancer. , 2001, International journal of molecular medicine.

[21]  M. Katoh Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer. , 2001, International journal of oncology.

[22]  T. Akiyama Wnt/beta-catenin signaling. , 2000, Cytokine & growth factor reviews.

[23]  H. Clevers,et al.  Linking Colorectal Cancer to Wnt Signaling , 2000, Cell.

[24]  P. Polakis Wnt signaling and cancer. , 2000, Genes & development.

[25]  P. Lichter,et al.  Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2 , 1998 .

[26]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[27]  C. Gespach,et al.  Evidence for the involvement of the Wnt 2 gene in human colorectal cancer. , 1996, Oncogene.

[28]  R. Nusse,et al.  Amplification and proviral activation of several Wnt genes during progression and clonal variation of mouse mammary tumors. , 1992, Oncogene.

[29]  J. Yokota,et al.  Human HST1 (HSTF1) gene maps to chromosome band 11q13 and coamplifies with the INT2 gene in human cancer. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Harold E. Varmus,et al.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome , 1982, Cell.

[31]  Ramon Silva Martins,et al.  Malignant pleural mesothelioma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  Amie Y Lee,et al.  A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. , 2004, Neoplasia.

[33]  J. Rubin,et al.  Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas , 2002, Oncogene.

[34]  P. Lichter,et al.  Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. , 1998, Genes, chromosomes & cancer.